Search

William W Hauswirth

from Ellicott City, MD
Age ~79

William Hauswirth Phones & Addresses

  • Ellicott City, MD
  • Knoxville, TN
  • Lake Bluff, IL
  • 12001 89Th St, Gainesville, FL 32608 (352) 495-3431
  • Lane, IL
  • Alachua, FL
  • Jessup, MD

Business Records

Name / Title
Company / Classification
Phones & Addresses
William W. Hauswirth
Treasurer, Director
Applied Genetic Technologies Corporation
Commercial Physical Research · Laboratories-Research & Develo
11801 Research Dr, Alachua, FL 32615
12085 Research Dr, Alachua, FL 32615
(386) 462-2204

Publications

Us Patents

Production Of Pseudotyped Recombinant Aav Virions

US Patent:
7094604, Aug 22, 2006
Filed:
Mar 11, 2004
Appl. No.:
10/798192
Inventors:
Richard O. Snyder - Gainesville FL, US
Sergei Zolotukhin - Gainesville FL, US
Yoshihisa Sakai - Gainesville FL, US
Barry J. Byrne - Gainesville FL, US
Mark R. Potter - Gainesville FL, US
Irine Zolotukhin - Gainesville FL, US
Scott Loiler - Gainesville FL, US
Vince A. Chiodo - Gainesville FL, US
Nicholas Muzyczka - Gainesville FL, US
William W. Hauswirth - Gainesville FL, US
Terence R. Flotte - Alachua FL, US
Corinna Burger - Gainesville FL, US
Edgardo Rodriguez - Gainesville FL, US
Kevin R. Nash - Gainesville FL, US
Thomas J. Fraites - Gainesville FL, US
Assignee:
University of Florida Research Foundation, Inc. - Gainesville FL
International Classification:
C12N 5/10
C12N 15/864
C12N 15/35
US Classification:
435457, 435325, 4353201, 435455, 435456, 536 231, 536 2372, 536 241
Abstract:
Vectors that encode Adeno-Associated Virus (AAV) Rep and Cap proteins of different serotypes and Adenovirus transcription products that provide helper functions were used to produce pseudotyped recombinant AAV (rAAV) virions. Purification methods generated pseudotyped rAAV virion stocks that were 99% pure with titers of 1×10–1×10vector genomes/ml.

Adeno-Associated Virus-Delivered Ribozyme Compositions And Methods Of Use

US Patent:
7342111, Mar 11, 2008
Filed:
Oct 21, 2005
Appl. No.:
11/256607
Inventors:
Alfred S. Lewin - Gainesville FL, US
William Hauswirth - Gainesville FL, US
Xiaoping Qi - Gainesville FL, US
Assignee:
University of Florida Research Foundation, Inc. - Gainesville FL
International Classification:
A61K 48/00
C12N 15/63
C07H 21/02
C07H 21/04
US Classification:
536 245, 4353201, 536 231, 514 44
Abstract:
Provided are methods for the identification of novel genes involved in a variety of cellular processes, including retinal degeneration, retinal disease, cancer, memory and learning, amylotropic lateral sclerosis, and methods for the identification of the function of a variety of genes and gene fragments of unknown function. The genes thus identified, as well as the compositions used in the identification methods, are also provided.

Method Of Treating Or Retarding The Development Of Blindness

US Patent:
8147823, Apr 3, 2012
Filed:
Jul 8, 2010
Appl. No.:
12/832282
Inventors:
Gregory M. Acland - Kennett Square PA, US
Gustavo D. Aguirre - Ithaca NY, US
Jean Bennett - Bryn Mawr PA, US
William W. Hauswirth - Gainesville FL, US
Samuel G. Jacobson - Penn Valley PA, US
Albert M. Maguire - Bryn Mawr PA, US
Assignee:
The Trustees of the University of Pennsylvania - Philadelphia PA
University of Florida Research Foundation, Incorporated - Gaineville FL
Cornell Research Foundation Inc. - Ithaca NY
International Classification:
A61K 48/00
C12N 15/12
C12N 15/861
US Classification:
424 936, 424 932, 435456, 514 44
Abstract:
A method for treating an ocular disorder characterized by the defect or absence of a normal gene in the ocular cells of a human or animal subject involves administering to the subject by subretinal injection an effective amount of a recombinant adeno-associated virus carrying a nucleic acid sequence encoding the normal gene under the control of a promoter sequence which expresses the product of the gene in the ocular cells. The ocular cells are preferably retinal pigment epithelial (RPE) cells, and the gene is preferably an RPE-specific gene, e. g. , RPE65. The promoter is one that can express the gene product in the RPE cells. Compositions for subretinal administration are useful in this method.

Self-Complementary Adeno-Associated Virus Having A Truncated Cmv-Chicken Β-Actin Promoter

US Patent:
8298818, Oct 30, 2012
Filed:
Apr 27, 2007
Appl. No.:
12/298845
Inventors:
Sanford Leon Boye - Gainesville FL, US
William W. Hauswirth - Gainesville FL, US
Barry John Byrne - Gainesville FL, US
Assignee:
University of Florida Research Foundation, Inc. - Gainesville FL
International Classification:
C12N 15/00
C12N 5/00
US Classification:
4353201, 435325
Abstract:
The present inventors concerns vectors carrying a truncated chimeric CMV-chicken β-actin (smCBA) promoter in which the hybrid chicken β-actin/rabbit β-globin intron is greatly shortened, and their use to deliver to an operatively linked polynucleotide to host cells in vitro or in vivo, resulting in expression of the polynucleotide in the host cells. In one embodiment, the vector carrying the smCBA promoter is administered to the eye. In another embodiment, the vector carrying the smCBA promoter is a self-complementary adeno-associated virus (AAV). The AAV vector may be of any serotype (e. g. , type 1, type 2, type 3, type 4, type 5, type 6, type 7, type 8, type 9, type 10). In another embodiment, a self-complementary vector carrying the smCBA promoter is administered to the eye. Another aspect of the invention concerns host cells carrying a vector of the invention. Another aspect of the invention concerns pharmaceutical composition comprising the vectors or host cells of the invention, and a pharmaceutically acceptable carrier.

Expression Of Glial-Derived Neurotrophic Factor For Treatment Of Diseases Of The Eye

US Patent:
20030129164, Jul 10, 2003
Filed:
Dec 2, 2002
Appl. No.:
10/308875
Inventors:
John Flannery - Berkeley CA, US
William Hauswirth - Gainesville FL, US
International Classification:
A61K048/00
C12N015/861
US Classification:
424/093200, 435/456000
Abstract:
The invention features methods and compositions for the treatment of disease of the eye, such as retinitis pigmentosa (RP) and glaucoma, by delivery of a neurotrophic factor, particularly glial cell-derived neurotrophic factor (GDNF) using a gene delivery vector. In one embodiment, the gene delivery vector is recombinant viral vector, particularly a recombinant adeno-associated viral (rAAV) vector.

Expression System For Abc Transporters

US Patent:
20030224485, Dec 4, 2003
Filed:
May 6, 2003
Appl. No.:
10/431323
Inventors:
Robert Molday - Vancouver, CA
Jinhi Ahn - Vancouver, CA
William Hauswirth - Gainesville FL, US
International Classification:
C07H021/04
C12P021/02
C12N005/06
C07K014/705
US Classification:
435/069100, 435/320100, 435/325000, 530/350000, 536/023500
Abstract:
The present invention provides a system and method for expressing a functional ABC (ATP-binding cassette) transporter in a host cell. A system comprises two or more expression vectors each comprising a nucleic acid molecule encoding one or more domains of the ABCR transporter gene and a means for expressing the nucleic acid molecule. Each expression vector of the system includes a nucleic acid molecule that encodes a domain that is functionally complementary to domains contained in the other expression vectors of the system but when taken together comprise the full ABCR transporter gene. Co-transfection of the expression vectors into a host cell provides co-expression of each of the domains of the protein which assemble to form an ABC transporter protein having functional characteristics of the full-length protein.

Method Of Treating Or Retarding The Development Of Blindness

US Patent:
20040022766, Feb 5, 2004
Filed:
Nov 20, 2002
Appl. No.:
10/300720
Inventors:
Gregory Acland - Kennett Square PA, US
Gustayo Aguirre - Ithaca NY, US
Jean Bennett - Bryn Mawr PA, US
William Hauswirth - Gainesville FL, US
Samuel Jacobson - Penn Valley PA, US
Albert Maguire - Bryn Mawr PA, US
International Classification:
A61K048/00
US Classification:
424/093200
Abstract:
A method for treating an ocular disorder characterized by the defect or absence of a normal gene in the ocular cells of a human or animal subject involves administering to the subject by subretinal injection an effective amount of a recombinant adeno-associated virus carrying a nucleic acid sequence encoding the normal gene under the control of a promoter sequence which expresses the product of the gene in the ocular cells. The ocular cells are preferably retinal pigment epithelial (RPE) cells, and the gene is preferably an RPE-specific gene, e.g., RPE65. The promoter is one that can express the gene product in the RPE cells. Compositions for subretinal administration are useful in this method.

Electroporation Device And Method For Delivery To Ocular Tissue

US Patent:
20050277868, Dec 15, 2005
Filed:
Jun 13, 2005
Appl. No.:
11/160182
Inventors:
Richard Heller - Tampa FL, US
Mark Jaroszeski - Tampa FL, US
Richard Gilbert - Tampa FL, US
William Hauswirth - Gainesville FL, US
Assignee:
UNIVERSITY OF SOUTH FLORIDA - Tampa FL
International Classification:
A61N001/30
US Classification:
604021000
Abstract:
In accordance with the present invention is provided a device and method for delivering DNA for the purpose of gene therapy to specific regions within and around the eye.
William W Hauswirth from Ellicott City, MD, age ~79 Get Report